RIPK3 and cancer: The thymus is the primary site of T cell development but both T and B cell lymphoma can arise in the thymus.[29] The most common thymic lymphoid neoplasms are Hodgkin's lymphoma, large‐cell lymphoma, and lymphoblastic lymphoma.[30] Extensive loss/reduction of RIPK3 expression in many cancers suggests its loss provides some kind of selective advantage to tumor cells and a defect of canonical necroptosis could be a central reason for tumor progression/tumor cell proliferation.[9a] However, we found that MLKL was hardly expressed in DP T lymphocytes from the thymus and in thymic lymphoma cells.